Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Core Insights - Ligand Pharmaceuticals will report its first quarter 2025 financial results on May 8, 2025, before U.S. market opening [1] - A conference call will be held on the same day at 8:30 AM ET to discuss the results and provide a business update [2] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing [3] - The company aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3] - The company operates two royalty-generating technology platforms: Captisol® for drug solubility and stability, and NITRICIL™ for tunable dosing and adjustable drug release profiles [3] - Ligand has established alliances with major pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]